Autoantibody production in cGVHD patients before and after rituximab treatment. (A) Autoantibody (anti-Ro52) levels measured by direct binding ELISA in cGVHD patients before and after rituximab treatment. Patients are grouped by clinical status of cGVHD at 2 years after rituximab. (B) Average OD reading in an ELISA detecting anti-Ro-52 IgG in the cGVHD group with stable/improved compared with progressive disease before rituximab by ELISA. Average ELISA OD reading in an ELISA assessing IgG reactivity to Epstein-Barr virus protein (EBNA) in patients over time after rituximab treatment was not different between groups (data not shown).